



国内版

国际版

Pseudo- and real progression under nivolumab in ovarian cancer: A case report and



All

Images

Videos

翻译成中文

关闭取词

112,000 Results

Any time ▾

## Pseudo-Meigs' syndrome due to ovarian metastases from ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) › ... › Surg Case Rep › v.2; 2016 Dec

**Pseudo-Meigs' syndrome due to ovarian metastases from colon cancer: a case report and review of the literature** Atsushi Yamamoto , 1 Yoshiaki Miyasaka , 1 Kazushige Furuya , 1 Hideki Watanabe , 1 Masahiro Maruyama , 1 Haruka Nakada , 1 Atsushi Takano , 1 Masao Hada , 1 Hiroshi Nakagomi , 1 Masao Omata , 2 and Toshio Oyama 3

## Pseudo-Meigs' syndrome due to ovarian metastases from ...

<https://surgicalcasereports.springeropen.com/articles/10.1186/s...> ▾

Oct 12, 2016 · **Pseudo-Meigs' syndrome due to ovarian metastases from colon cancer: a case report and review of the literature** Atsushi Yamamoto 1 Email author , Yoshiaki Miyasaka 1 ,  
**Author:** Atsushi Yamamoto, Yoshiaki Miyasaka... **Publish Year:** 2016

## Pseudo-Meigs' syndrome due to ovarian metastases from ...

<https://link.springer.com/article/10.1186/s40792-016-0209-7> ▾

We herein report a case with **pseudo-Meigs' syndrome** that developed both synchronous and metachronous metastases to the ovary from ascending colon cancer and review of the pertinent literature. Case presentation

**Author:** Atsushi Yamamoto, Yoshiaki Miyasaka... **Publish Year:** 2016

## Cystic struma ovarii presenting as pseudo-Meigs' syndrome ...

[https://www.researchgate.net/publication/5518269\\_Cystic\\_struma...](https://www.researchgate.net/publication/5518269_Cystic_struma...)

Cystic struma ovarii presenting as **pseudo-Meigs' syndrome** with elevated CA125 levels. A case report and review of the literature

## Precise preoperative diagnosis of struma ovarii with ...

<https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048...> ▾

Feb 02, 2018 · Precise preoperative diagnosis of struma ovarii with **pseudo-Meigs' syndrome** mimicking ovarian cancer with the combination of 131 I scintigraphy and 18 F-FDG PET: case report and review of the literature

**Author:** Sayaka Fujiwara, Hideaki Tsuyoshi, To... **Publish Year:** 2018

1

**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 45554

**Manuscript Type:** CASE REPORT

**Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report**

Passler M *et al.* Pseudo- and real progression under nivolumab in ovarian cancer

Mona Passler, Eliane T Taube, Jalid Sehouli, Klaus Pietzner

**Abstract**

**BACKGROUND**

Checkpoint-Inhibition has revolutionized the treatment for several entities such as

**Match Overview**

**1** Crossref 14 words  
"Oncoimmunology", Springer Nature, 2018 <1%  
SIMILAR





All

Images

Videos

翻译成中文

关闭取词

39,200 Results

Any time ▾

## All Pseudo Progression, Recurrence and Necrosis messages

<https://www.cancercompass.com/message-board/message/all,65764,0.htm> ▾

Apr 22, 2012 · RE: **Pseudo Progression, Recurrence and Necrosis**. The problem is that if it is **pseudo progression**, it will naturally go away, usually within the next 3 months. The **patient** needs to continue the chemo right on through it, otherwise, the lapse in **chemo** can encourage **real tumor growth** to ...

## Pseudoprogression and Immune-Related Response in Solid ...

<https://ascopubs.org/doi/full/10.1200/JCO.2015.61.6870>

Aug 10, 2015 · The initial **report** of immune-related response criteria in **patients** who received ipilimumab for treatment of melanoma found that 9.7% of **patients** (22 of 227 **patients**) had clinical responses (partial response and stable disease) that would have been misclassified as disease **progression** by WHO criteria. 7 **Patients** who had responses consistent with ...

Cited by: 368

Author: Victoria L. Chiou, Mauricio Burotto

Publish Year: 2015

## Pseudo-Meigs' syndrome due to ovarian metastases from ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061673>

Review of literatures of **pseudo-Meigs' syndrome** due to **ovarian** metastases from colon **cancer**. The mean age was  $49 \pm 9$  years (range 32–65 years), and the primary site of colorectal cancers included the cecum 2, ascending colon 6, transversus colon 1, descending colon 2, sigmoid colon 13, and rectum 4 **patients**.

## Checkpoint Inhibitor Related Pseudoprogression in NSCLC

<https://www.onclive.com/.../checkpoint-inhibitor-related-pseudoprogression-in-nsclc> ▾

Feb 11, 2014 · In general, 50% of **patients** treated with **nivolumab** respond within 8 weeks, and initial **progression** should not be grounds for treatment discontinuation with checkpoint inhibitors, Levy notes.

## Nivolumab use for BRCA gene mutation carriers with ...

<https://www.sciencedirect.com/science/article/pii/S2352578918300626>

**Nivolumab** use for BRCA gene mutation carriers with recurrent epithelial **ovarian cancer**: A case series. ... version 5.0). **Progression**-free survival was defined as the time interval between the initiation of **nivolumab** and the first **progression** of disease or death. ... In another **patient** (Case 2) **nivolumab** treatment was held due to developing ...

Cited by: 4

Author: Koji Matsuo, Samantha E. Spragg, Marc...

Publish Year: 2018



16,900 Results

Any time ▾

## Pseudoproggression and Immune-Related Response in Solid ...

<https://ascopubs.org/doi/full/10.1200/JCO.2015.61.6870>

Aug 10, 2015 · The initial report of immune-related response criteria in patients who received ipilimumab for treatment of melanoma found that 9.7% of patients (22 of 227 patients) had clinical responses (partial response and stable disease) that would have been misclassified as disease progression by WHO criteria. 7 Patients who had responses consistent with ...

Cited by: 363

Author: Victoria L. Chiou, Mauricio Burotto

Publish Year: 2015

## All Pseudo Progression, Recurrence and Necrosis messages

<https://www.cancercompass.com/message-board/message/all,65764,0.htm> ▾

Apr 22, 2012 · RE: Pseudo Progression, Recurrence and Necrosis. The problem is that if it is pseudo progression, it will naturally go away, usually within the next 3 months. The patient needs to continue the chemo right on through it, otherwise, the lapse in chemo can encourage real tumor growth to ...

## Pseudoproggression manifesting as recurrent ascites with ...

<https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0334-x> ▾

Apr 04, 2018 · In melanoma, 28% of patients treated beyond progression with the anti-PD1 inhibitor nivolumab had subsequent responses with greater than 30% reduction in target lesion size. Reports analyzing tumor tissue in this setting have reported the influx of T lymphocytes and other immune cells . Pseudoproggression is an important phenomenon to recognize and understand, since it may result in inappropriately discontinuing therapy in a patient ...

Cited by: 2

Author: Randy F. Sweis, Yuanyuan Zha, Lomax P...

Publish Year: 2018

## :: JGO :: Journal of Gynecologic Oncology - ejgo.org

<https://ejgo.org/DOIx.php?id=10.3802/jgo.2019.30.e56> ▾

Programmed cell death-ligand 1 (PD-L1) expression is associated with poor prognosis, and it is known that PD-L1 promotes progression of ovarian cancer [6, 7]. A phase II clinical trial demonstrated that nivolumab, a programmed cell death protein 1 (PD-1) receptor blocker, was well-tolerated and offered a disease control rate of 45% .

## Hyperprogressive Disease in the Irradiation Field after a ...

[https://www.researchgate.net/publication/323619001\\_Hyperprogressive\\_Disease\\_in\\_the...](https://www.researchgate.net/publication/323619001_Hyperprogressive_Disease_in_the...)

We report a patient with gastric cancer who received nivolumab after radiotherapy only to experience rapid progression within the irradiation field after the first immunotherapy session.

## Immunotherapy for Kidney Cancer: The Past, Present, and ...

<https://www.accc-cancer.org/home/learn/immunotherapy/resource-detail/Immunotherapy-for...> ▾